Real‐World Outcomes of Patients with Metastatic Non‐Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

BACKGROUND. Evidence from cancer clinical trials has strong internal validity but can be difficult to generalize to real‐world patient populations. Here we analyzed real‐world outcomes of patients with metastatic non‐small cell lung cancer (mNSCLC) treated with programmed cell death protein 1 (PD‐1)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Khozin, Sean, Carson, Kenneth R., Zhi, Jizu, Tucker, Melisa, Lee, Shannon E., Light, David E., Curtis, Melissa D., Bralic, Marta, Kaganman, Irene, Gossai, Anala, Hofmeister, Philip, Torres, Aracelis Z., Miksad, Rebecca A., Blumenthal, Gideon Michael, Pazdur, Richard, Abernethy, Amy P.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516117/
https://ncbi.nlm.nih.gov/pubmed/30591549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados